Effect of antitumour necrosis factor‐<i>α</i> therapy on bone turnover in patients with active Crohn's disease: a prospective study

Abstract

Infliximab therapy had a significant beneficial effect on bone metabolism in patients with active Crohn's disease. These findings further support the theory that active ongoing inflammation and high levels of circulating cytokines play a pivotal role in the pathogenesis of bone loss in patients with Crohn's disease.